Organovo Holdings (consolidare)

Organovo Holdings, Inc.(http://organovo.com/) is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

• Organovo Holdings (consolidare)